Current Studies

Study 12311

Who is suitable for the investigation?

Men and women

Rheumatoid arthritis patients

Aged 20 to 75 years.

 

BMI 19 – 36

 

Weight 50 – 145kg

 

How much will payment will I receive?  £2250.* 

*This is to cover your time and any out of pocket expenses.  You should note that any travel expenses incurred, will be met by yourself. The amount shown is for completion of the investigation.

 

How long will I have to stay?  The investigation involves one period of stay and 21 outpatient visits (plus a screening appointment) in our modern Belfast City Centre based clinic.  The dates for the study are as follows:

Period of Stay       

Period 1: Wednesday 13^th June 2012 8am  to Friday 15^th June 2012 approx. 10am

Outpatient visits will be arranged with you by a member of the clinic team.                        

You must be available to stay on ALL sets of dates for your group. 

Why is the study being carried out?  The drug being tested in this study is called MED15117 and it is being developed for the treatment of inflammatory pain, which is a symptom of many diseases including rheumatoid arthritis. This is the first time the drug has been tested in humans. The purpose of this study is to assess the safety and tolerability of a single dose of MED15117 in patients with rheumatoid arthritis. You will receive one of a possible four dose strengths of MED15117 or a placebo

What else should I know?  To make sure that you are suitable for this study you will have to undergo a thorough medical.  Details of which will be discussed with you prior to attending the medical.

If you pass the medical you may be invited to participate in this investigation.  

Screening Medicals will take place on the following dates:

Monday 21^st May 2012

Study 10412

Who is suitable for the study?        

• Males and females with peripheral neuropathic pain for longer than 6 months
• Aged 18-65
• Body Mass Index (BMI) 18 – 32 (We can check this for you)

How much will payment will I receive? 

Up to £2250

 (This is to cover your time and any out of pocket expenses.  You should note that any travel expenses incurred, will be met by yourself. The amount shown is for completion of the study.)

 

How long will I have to stay? 

The study involves one outpatient visit followed by a 14 day period of stay in our modern Belfast City Centre based clinic followed by plus 2 return visits.     

 

Stay:                Saturday 16^th June 2012 to Friday 29^th June 2012

Return:            Thursday 5^th July 2012

Return:            Wednesday 25^th July 2012

 

You must be available to stay on ALL sets of dates for your group. 

 What is the study drug? 

The study drug is GRT6010 which is being developed to treat patients with chronic peripheral neuropathic pain. This may be present due to previous surgery, trauma or infection.   

What else should I know? 

To make sure that you are suitable for this study you will have to undergo a thorough medical.   Details of which will be discussed with you prior to attending the medical.

If you pass the medical you may be invited to participate in the study. 

It will also be necessary to attend a medical a few days after you finish the study.

 

If you would like to hear more details about the study, and to book a medical, please call our recruitment team on 028 90 81 83 85 and quote ref 10412

Medicals to determine eligibility for this study will take place in the morning on the following dates:

Wednesday 23rd May 2012(lasting approx. 2-3hours)

Thursday 24^th May 2012 (lasting approx. 2-3hours)

Monday 28^th May 2012 (lasting approx. 2-3hours)

Study 10611

BioKinetic are currently looking for men and women who have rheumatoid arthritis to take part in a research study.  The study is testing a new type of monoclonal antibody therapy called secukinumab. The aim of the drug is to interfere with the inflammation associated with rheumatoid arthritis. In the study we will also be using a placebo medication- this is a sterile solution that contains no active drug, prepared to look and be given in the same way as the study drug. Neither you nor the staff will know if you are receiving secukinumab or the placebo until week 12 of the study.

How long will I have to stay? 

The study involves 8 visits to our Belfast City Centre based clinic over the initial 12 weeks, beginning with 2 consecutive days and then once every 2 weeks. 

Depending on what treatment it is disclosed that you have been receiving during the initial 12 weeks (secukinumab or placebo), and the results from the study drug, there are 3 possible ways to progress after week 12.

The options following week 12 are as follows:

• One clinic visit during week 16 OR
• Clinic visits every 4 weeks until week 24 (3 visits) OR
• Clinic visits every 4 weeks until week 36 (6 visits)

You must be available to attend the clinic on ALL requested dates. 

Who is suitable for the study?        

• Males and females who have been diagnosed by their GP or rheumatologist as having rheumatoid arthritis
• Aged 18 years and over
• Not used or using high strength opioids such as morphine, hydromorphone or methadone
• No other significant health issues

How much will payment will I receive? 

You will be reimbursed your travel expenses.

What else should I know? 

To make sure that you are suitable for this study you will have to undergo a thorough medical.  Details of which will be discussed with you prior to attending the medical.

If you pass the medical you may be invited to participate in the study. 

It will also be necessary to attend a medical a few days after you finish the study.

If you would like to hear more details about the study, and to book a medical, please call our recruitment team on 028 90 81 83 85 and quote ref 10611

Find a study

Study 12311                        BioKinetic are looking for rheumatoid arthritis patients to take part in a study testing a new drug being developed to treat the disease

Study 10412    BioKinetic are currently looking for men and women who currently suffer from peripheral neuropathic pain to take part in a research study.  Neuropathic pain (burning, shooting, stabbing or electric shock type pain cause by one of the following triggers; scar pain after a mastectomy or thoracotomy, nerve pain cause by surgery or injury to the arms or legs, or caused by shingles.

Study 10611 

BioKinetic are currently looking for men and women who have rheumatoid arthritis to take part in a research study.  The study is testing a new type of monoclonal antibody therapy called secukinumab. The aim of the drug is to interfere with the inflammation associated with rheumatoid arthritis. In the study we will also be using a placebo medication- this is a sterile solution that contains no active drug, prepared to look and be given in the same way as the study drug. Neither you nor the staff will know if you are receiving secukinumab or the placebo until week 12 of the study.